Application of Human iPS Cell-Derived Models for Highly Predictive Toxicity Screening

This poster presents the development of an industrial-scale manufacturing platform for the production of terminally-differentiated, human iPS cell-derived tissue types (e.g. neurons, cardiomyocytes, and hepatocytes) that are highly pure (>95%) and exhibit normal genotypic, phenotypic, and functional characteristics of native cells.